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Osteoarthritis (OA) of the knee and hip is a debilitating disease affecting more women than men and the
risk of developing OA increases precipitously with aging. Rheumatoid arthritis (RA), the most common
form of inflammatory joint diseases, is a disease of unknown etiology and affects  1% of the population
worldwide, and unlike OA, generally involves many joints because of the systemic nature of the disease.
Non-steroidal anti-inflammatory drugs (NSAIDs) are the first drugs of choice for the symptomatic treat-
ment of both OA and RA. Because of the risks associated with the use of NSAIDs and other limitations,
the use of alternative therapies, such as acupuncture and medicinal herbs, is on the rise and according to
reports  60–90% of dissatisfied arthritis patients are likely to seek the option of complementary and
alternative medicine (CAM). This paper reviews the efficacy of some of the common herbs that have
a history of human use and their anti-inflammatory or antiarthritic properties have been evaluated in
animal models of inflammatory arthritis, in studies employing well defined and widely accepted in vitro
models that use human chondrocytes/cartilage explants or in clinical trials. Available data suggests that
the extracts of most of these herbs or compounds derived from them may provide a safe and effective
adjunctive therapeutic approach for the treatment of OA and RA. This, in turn, argues for trials to
establish efficacy and optimum dosage of these compounds for treating human inflammatory and
degenerative joint diseases.
Keywords: cats claw – curcumin – ginger – green tea – inflammation – osteoarthritis – rheumatoid
arthritis
Introduction
Osteoarthritis (OA) of the knee and hip is a debilitating disease
and the risk increases precipitously with aging. The severity of
OA varies from person to person, but the consonant clinical
signs include pain, reduced range of motion, inflammation
and deformity (1,2). OA and other rheumatic diseases cur-
rently affect >43 million Americans with the number expected
to increase to an estimated 60 million by the year 2020 (3,4).
The high prevalence of OA with its associated loss of joint
function results in expensive and long-term conventional ther-
apies that poses a significant socioeconomic burden. This fact
alone makes OA a significant health and economic challenge.
When clinically evident, OA is characterized by joint pain,
tenderness, limitation of movement, crepitus, occasional effu-
sion and variable degrees of inflammation without systemic
effects. Although not a traditional inflammatory disease,
symptoms of local inflammation and synovitis are present in
many patients of OA and also seen in animal models of OA
[reviewed in (5)]. The presence of elevated levels of proin-
flammatory cytokines IL-1 and TNF-a has been demonstrated
in OA synovial fluid and it has been shown that proinflammat-
ory cytokines can stimulate the expression of inflammatory
mediators and matrix degrading metalloproteinases in an
arthritic joint [(6,7) and references therein]. Pharmacological
management of OA includes the administration of analgesics
and non-steroidal anti-inflammatory drugs (NSAIDs), but their
use does not provide adequate pain relief in some patients.
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(RA) represents the most common form, is a chronic and
systemic inflammatory disease of unknown etiology and is
marked by synovial hyperplasia with local invasion of bone
and cartilage leading to joint destruction (8,9). RA affects
 1% of the adult population with more women being afflicted
than men [(3,10) and references therein]. Recent reports sug-
gest that patients with RA not only have a higher chronic dis-
ease burden [(11,12) and references therein] but may also
have increased morbidity and mortality from cardiovascular
disease compared with persons without RA (13). RA patho-
genesis is regulated by proinflammatory cytokines such as
IL-1 and TNF-a that activate a broad array of intracellular
signal transduction mechanisms (14–16). In RA, migration of
leukocytes into the synovial tissue (ST) occurs. These leuko-
cytes and other cells in the ST, particularly RA ST fibroblasts,
produce several mediators of inflammation, including
chemokines—chemotactic cytokines that recruit leukocytes
to the inflamed joint and also play a role in angiogenesis
[(17) and references therein].
Like OA, current treatment modalities for RA are mostly
symptomatic although recently it has been suggested that use
of disease-modifying antirheumatic drugs (DMARDs) has led
to important gains in our overall ability to treat RA patients,
resulting in a better health status for patients with RA (18).
The value of DMARDs for treating OA or RA is also limited
by their side effects and the fact that they are more expensive
to use than traditional NSAIDs. The major side effects of
NSAIDs are their propensity to cause stomach ulcers, GI
bleeding and perforations. Although a new class of
NSAIDs—the specific inhibitors of COX-2—was developed,
these drugs have similar efficacy as the general NSAIDs but
are safer with respect to gastrointestinal toxicity. However,
some of these COX-2 inhibitors were recently withdrawn
from the market or ordered by the United States Food and
Drug Administration (FDA) to have a black box warning on
the label because of concerns that their long-term use may
increase the risk of stroke and heart attack.
However, despite optimal use of currently available anti-
rheumatic agents, most RA patients live with chronic pain
and severe functional decline because these therapies focus
primarily on preventing joint inflammation and soft tissue
swelling, but are not effective in preventing cartilage break-
down and the joint destruction associated with RA.
Recently, efforts have been focused on using the class of
drugs called biologics (antibodies or soluble receptors for IL-1,
IL-6 and TNF-a) for the treatment of OA and RA. Although
these agents reduce inflammation and joint destruction, their
long-term risks and benefits are not yet clear. Additionally,
higher costs and the findings that they are not effective univer-
sally and severe side effects such as life-threatening infections
and increased risk of malignancies limit the use of such agents
in many populations (19–23). Thus, a final assessment on the
use of biologics for the treatment of RA or OA, particularly
with regard to risk of infections, malignancies and autoanti-
body production has to be carefully monitored.
Because of these and other limitations, the use of comple-
mentary and alternative medicine (CAM) therapies, such as
acupuncture and extracts of medicinal herbs, is on the rise
and according to reports  60–90% of dissatisfied arthritis
patients are likely to seek the option of CAM therapy (24,25).
While most of the rheumatologists and other clinicians are
skeptical of CAM therapies, patients who use CAM appear to
be satisfied with the self-care approach. This self-satisfaction
is mostly based on the notion that since these herbs and plants
are found in nature, remedies derived from them must be safe.
However, the long-term safety and efficacy of most of the her-
bal preparations commonly promoted as antiarthritic have not
been established by placebo-controlled randomized trials
either in OA or RA patients and indeed some of these may
even interfere with the ongoing treatments. Therefore, it is
imperative that scientific evidence regarding the safety and
efficacy of herbal preparations commonly used by arthritis
patients be presented to both the physicians and the patients
helping them in making informed decisions. The objective of
this review is to summarize the currently available information
on selective herbal preparations that are commonly consumed
by arthritis patients.
Historical Perspective
Herbal medicine is the root of various traditional medicine
systems around the world. Botanicals are a chemical source
that directly provides  25% of currently used crude drugs,
with another 25% derived from chemically altered natural
products (26). Various traditional medicine systems around
the world, including ancient Chinese medicinal system, Indian
medicinal system (composed of two major branches—Unani
and Ayurveda) and Amazonian ethnomedicine, rely heavily
on herbs for health preservation and healing. Herbal medicines
have been described in traditional texts and used as antimicro-
bial, anti-inflammatory and antiviral medicine for the cure of
allergies, RA, infections, wound healing and fever (27). Arth-
ritis (both OA and RA) is one of the foremost diseases for
which patient seeks the CAM option (28,29). Because there
is little evidence about the long-term effects of currently avail-
able traditional medicines and its associated adverse effects,
the American College of Rheumatology recommends the care-
ful use of dietary supplements and herbal medicines during
early stages of treatment or disease development to limit the
degree of joint destruction.
It is no surprise, then, that the use of alternative medicine,
such as botanicals and nutritional supplements, has become
popular with arthritis patients and is on the rise. An increasing
number of people in the United States, as many as 42% use
complementary or alternative medicine approaches to help
meet their personal health problems (29,30). This review
describes the currently available scientific evidence that
regarding the efficacy and toxic effects, if known, of Camellia
sinensis (green tea) (Fig. 1A), Uncaria tomentosa (cat’s claw)
(Fig. 1B), Tripterygium wilfordii Hook F (Fig. 1C), Curcuma
longa (turmeric) (Fig. 1D) and Zingiber officinale (ginger)
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agents for the treatment of RA and OA.
C. sinensis (green tea)
Green tea (Fig. 1A) is one of the most commonly consumed
beverages in the world with no reported side effects. The
established pharmacological properties of green tea are
attributed to its high content of polyphenols/catechins, mainly
epigallocatechin-3-gallate (EGCG) (31). The potential
disease-modifying effect of green tea on arthritis came to light
when it was shown that collagen type II-induced arthritis
(CIA) in mice, an animal model of inflammatory polyarthritis,
was ameliorated by prophylactic administration of green tea
polyphenols (GTPs) in drinking water (32). The reduced CIA
incidence and severity was reflected in a marked inhibition
of the inflammatory mediators COX2, interferon-g and TNF-
a in arthritic joints of green tea-fed mice. The activity of neut-
ral endopeptidase, an enzyme capable of breaking peptides at
neutral pH to block their biological actions, was found to be
 7-fold higher in arthritic joints of non-GTP-fed mice in com-
parison to non-arthritic joints of unimmunized mice, but only
2-fold higher in the arthritic joints of GTP-fed mice. Addition-
ally, total immunoglobulins (IgG) and type II collagen-specific
Figure 1. Plants and herbs most commonly used in CAM practices for the treatment of rheumatic diseases. [Images courtesy of Dr Hasan Mukhtar, University of
Wisconsin-Madison (A); Rainforest Nutrition, Inc., (B.1 and B.2); Dr Xullien Tao, NIAMS/NIH (C); Dr V. A. Parthasarthy, Indian Institute of Spice Research,
Kerala, India (D and E).]
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of GTP-fed mice. The reduction in biochemical markers
correlated with the marked reduction of inflammation in the
synovium seen on histopathology.
Mechanism of Action
Several studies have shown that most of the effects of green tea
extract are mimicked by its constituent polyphenol EGCG
(31,33). Consequently, further studies were conducted using
this compound and it was found that in human chondrocytes
derived from OA cartilage EGCG inhibited the transcription
factor nuclear factor kappaB (NF-kB) in conjunction with
IL-1b-inducible nitric oxide synthase (iNOS) and COX-2,
resulting in reduction of nitric oxide (NO) and prostaglandin
E2(PGE2) in vitro (34,35). It has also been shown that
EGCG selectively inhibits the IL-1b-induced phosphorylation
of c-Jun-N-terminal kinase (JNK) p46 isoform resulting in
lower levels of phospho-c-Jun and DNA-binding activity of
activation protein-1 (AP-1), a transcription factor implicated
in the inflammatory response, in human OA chondrocytes
(36). This is important since JNK kinase is a prime culprit in
inflammatory and degenerative diseases (37–40).
Matrix metalloproteinases (MMPs) are produced by activ-
ated chondrocytes and other cell types in an arthritic joint.
Physiologically, they take part in remodeling although excess-
ive production in the joint results in cartilage degradation.
Among the MMPs, MMP-1 and MMP-13 levels are found to
be significantly elevated in both OA and RA arthritic joints
(1,41,42). Recent studies have revealed that pretreatment of
human OA chondrocytes with EGCG significantly, in a dose-
dependent manner, inhibited the expression and activities of
MMP-1 and MMP-13 (IC50 values 27 and 16.5 mM, respect-
ively) in vitro (43). It has also been shown that EGCG was
equally effective in inhibiting IL-1b-induced MMP-1, -3 and
-13 in human tendon fibroblasts (44). Also, it was recently
shown that catechins from green tea inhibited the degradation
of human cartilage proteoglycan and type II collagen, and
selectively inhibited the aggrecanases called a disintegrin and
metalloproteinase with thrombospondin motifs (ADAMTS)-
1, -4 and -5 (45,46). Thus, there is experimental evidence to
support further studies to investigate the anti-inflammatory
and chondroprotective effects of green tea at the molecular
level. With the global availability of green tea, its low cost
and proven lack of toxicity, green tea catechins or compounds
derived from them could one day be useful as a conventional
medicine or as effective adjunct therapies for the treatment
of both RA and OA.
Cat’s Claw (U. tomentosa, U. guianensis)
Cat’s claw is a Peruvian vine with medicinal properties that are
well-documented in alternative medicine literature. Extract
of cat’s claw has been shown to possess antioxidant, anti-
inflammatory and immunomodulating properties [reviewed
in (47), also see (48)]. Extracts or preparations from the two
species U. tomentosa (Fig. 1B.1) or U. guianensis (Fig. 1B.2)
are interchangeably used to treat various inflammatory and
non-inflammatory conditions in the Peruvian medicinal sys-
tem. The chemical composition of the aqueous extract of
U. tomentosa vine includes oxindole alkaloids (virtually
absent in U. guianensis) tannins, quinovic acid, glycosides,
flavonoids and sterols (49). The most investigated of the active
constituents in U. tomentosa extract for immunomodulating
and anti-inflammatory effects are pentacyclic oxindole alkal-
oids, which are reported to induce a yet unknown immune
regulating factor (47). However, the antioxidant and anti-
inflammatory effects of the extracts of U. tomentosa and
U. guianensis appear to be independent of their alkaloid con-
tent as in several assays U. guianensis was more potent in
free radical scavenging and inhibition of TNF-a production
by mouse macrophages (50). In another study, Piscoya and
co-workers (51) evaluated the safety and side effects of
U. guianensis extract in patients with OA of the knee. Pain
associated with activities of daily living was significantly
reduced, although pain at rest or at night was not reduced dur-
ing this 4 week trial period. In another study, the use of an
extract of cat’s claw from the part of the vine that is rich in
pentacyclic alkaloids (roots) showed a reduction in the number
of painful joints when compared to placebo in patients with
RA (by 53.2 versus 24.1%; P ¼ 0.044) (52). Since no adverse
effects were reported, this small preliminary study demon-
strated the relative safety and modest benefit to the tender joint
count of a highly purified extract from the pentacyclic chemo-
type of U. tomentosa in patients with active RA taking sulfas-
alazine or hydroxychloroquine (52).
Several other groups have documented the safety and phar-
macological profile of cat’s claw in animal models and also
showed that cat’s claw was non-toxic in in vitro bioassays
[(47,50–54) and references therein]. Several standardized
extracts of cat’s claw are available commercially and different
dosages have been recommended for different conditions, but
effectiveness of these recommended doses has not been rigor-
ously tested. In some cases, mild nausea may occur upon
ingestion of crude extracts or teas (perhaps due to micropulver-
ized bark in some preparations), but other than diarrhea in
some cases no other gastrointestinal events have been associ-
ated with these herbs (47,51,52,54). Indeed, studies in animal
models have documented that cat’s claw is protective to the
gastrointestinal tract and suggests that the use of cat’s claw
extract may even protect the gut from the damaging effects
of NSAIDs (55). Although, in recommended dosages use of
cat’s claw is considered non-toxic, and there are no known
contraindications or drug interactions, this aspect has not
been rigorously investigated. Until the effects of these Peru-
vian herbs are better known, it is advisable to avoid their use
in women attempting pregnancy, during pregnancy and lacta-
tion, and for children <3 years of age (47,54).
Mechanism of Action
The antioxidant and anti-inflammatory activity of cat’s
claw extract was characterized in studies using the murine
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that cat’s claw extract was effective in inhibiting lipo-
polysaccharide (LPS)-induced free radical production and
subsequent lipid peroxidation in these cell types (55). In
addition, the authors also showed that TNF-a production
and iNOS expression via NF-kB expression were also
inhibited by the cat’s claw extract. Although not yet fully
elucidated, the antioxidant and immunomodulating proper-
ties of the compounds certainly appear to be important in
their anti-inflammatory action. These studies are important
enough to support more extensive studies before long-term
controlled trials of cat’s claw extracts, or active compounds
therein, can be initiated in large number of human subjects
to determine their long-term efficacy and safety profile.
T. wilfordii Hook F
T. wilfordii Hook F (TwHF) is a perennial vine-like plant that
grows in Southern China and Taiwan and is also known as
‘ThunderGodVine’(Fig.1C).Themedicinalextractisderived
from the root and has been used for the treatment of various
autoimmune and inflammatory diseases including RA, sys-
temic lupus erythematosus, nephritis, psoriasis and asthma
for several centuries (56). An ethanol/ethyl acetate extract of
TwHF showed therapeutic benefit in patients with treatment-
refractory RA (57). At the dosages used, the TwHF extract
was well tolerated by most patients in this study. A prospect-
ive, double-blind, placebo-controlled study of TwHF ethanol/
ethyl acetate extracts with RA patients has also been reported
(58). With a two-dose regimen, (180 and 360 mg day
 1)
used for 20 weeks, patients at the higher dose achieved a rapid
ACR-20 response with 50% of patients improving during the
first 4 weeks of treatment.
Both treatment groups showed a significant decrease in the
number of tender and swollen joints and improvement in the
physician’s global assessment. In another phase-I study, eight
out of nine patients treated with TwHF extract (>360 mg
day
 1) showed improvements in both clinical manifestations
and laboratory findings (58). One patient met American Col-
lege of Rheumatology criteria for remission. Based on these
data it was concluded that the extract of TwHF at dosages up
to 570 mg day
 1 appeared to be safe, and doses >360 mg
day
 1 were associated with clinical benefit in patients with
RA. In both of these studies, no toxic or adverse effects other
than diarrhea were observed in patients receiving the highest
dose. Topical application of TwHF was also tested in a ran-
domized, double-blind, placebo-controlled trial using 61
patients with RA and the authors concluded that topical
application of TwHF was efficacious in improving ACR-20
score (59).
In these and other studies, the most common side effects of
TwHF were vomiting, hair loss, diarrhea, headaches, dryness,
abdominal pain and vaginal spotting. TwHF usage can also
lead to the development of amenorrhea, which is reversible if
present for <2 years in patients <40 years of age but irrevers-
ible in perimenopausal women patients (56).
Mechanism of Action
The immunosuppressive and anti-inflammatory effects of
TwHF are believed to be mediated by one of its biologically
active constituent Triptolide (60). In animal studies, triptolide
inhibited the CIA in mice and rats (61,62) and markedly sup-
pressed the IL-1 and LPS-induced production of proMMP-1
and proMMP-3 in cultured synovial fibroblasts and mouse
macrophages (63). Recent studies showed that triptolide inhib-
ited iNOS gene expression by downregulating NF-kB DNA-
binding activity and JNK pathway (64). In other studies,
TwHF extract or its active constituent Triptolide were shown
to inhibit LPS- and cytokine-induced expression of COX-2,
MMP-3 and MMP-13 in articular chondrocytes (65). Tripto-
lide has also recently been shown to inhibit the IL-1, IL-17
and TNF-a-induced expression of aggrecanase gene in human
chondrocytes (66). An additional mechanism of its anti-
inflammatory effect may be via suppression of adhesion
molecules E-selectin, ICAM-1 and VCAM-1 (67). These and
other studies provide strong evidence regarding the scientific
basis of the known beneficial effects observed in RA patients,
but the molecular mechanism by which TwHF extracts or
triptolide inhibit RA disease severity is yet to be elucidated.
The above in vitro and other studies support the conclusion
that TwHF extract or its biologically active constituent tripto-
lide is efficacious in RA. Its efficacy in OA has not yet
been determined but data from in vitro studies (63–66)
strongly suggests that TwHF should be evaluated in animal
models as a first step for its possible use in the prevention or
treatment of OA.
C. longa (turmeric)
Turmeric is a widely used spice and coloring/flavoring agent
that comes from the root of the plant C. longa (Fig. 1D), a
member of the Zingaberacea family (68). The FDA classified
turmeric among substances ‘generally recognized as safe’. In
Ayurveda, turmeric has been used for various medicinal condi-
tions including rhinitis, wound healing, common cold, skin
infections, liver and urinary tract diseases and as a ‘blood puri-
fier’ (68–70). Turmeric was found to be effective even when
given by different routes including topical, oral or by inhala-
tion, dependent on the intended use. The major constituent of
turmeric is curcumin (diferuloylmethane), which constitutes
up to  90% of total curcuminoid content, with demethoxy-
curcumin and bis-demethoxycurcumin comprising the remain-
der (68). In animal studies, oral administration of curcumin to
rats decreased the levels of inflammatory glycoprotein, Gp A
72, with a reduction in paw inflammation (71). Curcumin has
also been shown to inhibit the carrageenin-induced paw edema
in mice and rats, with an ED50 dose 48 and 100.2 mg kg
 1,
respectively (71,72). In a double-blinded crossover clinical
trial of 18 patients with RA given curcumin (1200 mg day
 1)
for 2 weeks followed by 300 mg day
 1 of phenylbutazone
for another 2 weeks, respondents showed a significant
improvement in morning stiffness, walking time and reduction
in joint swelling (73).
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Curcumin is a non-toxic dietary pigment in turmeric and is
potent inhibitor of the common transcription factor NF-kBi n
several cell types (74–76). Other studies have shown that cur-
cumin inhibits/modulates upstream pathways of the arachido-
nic acid cascade (COX-2 and LOX) by inhibiting the
catalytic activities of phospholipases A2, Cg1 and D in various
cell lines (77–79). In human chondrocytes, curcumin signific-
antly inhibited MMP-3 and MMP-13 gene expression by
inhibiting the JNK, AP-1 and NF-kB pathways (75). Other
studies have shown that curcumin blocks LPS and interferon-
g-induced production of NO and TNF-a in vitro by inhibiting
the activation of NF-kB and AP-1 [reviewed in (68)].
Curcumin also inhibited the incorporation of arachidonic
acid into membrane lipids, PGE2 production, leukotriene
B4 and leukotriene C4 synthesis, as well as the secretion
of collagenase, elastase and hyaluronidase by macrophages
(78). Furthermore, IL-1b-induced upregulation of MMP-3 was
inhibited by curcumin in a time-dependent manner. In addi-
tion, IL-1b-induced decrease in type II collagen synthesis
was also blocked by curcumin treatment. Based on the data
obtained it was concluded that curcumin antagonizes crucial
catabolic effects of IL-1b signaling that are known to contrib-
ute to the pathogenesis of OA. Although not conclusive, but
these data clearly show the necessity of additional studies to
develop and use optimized doses in randomized, placebo-
controlled clinical trials to confirm or refute the reported
efficacy of the use of curcumin in OA and RA.
Z. officinale (ginger)
Ginger, the rhizome of Z. officinale (Fig. 1E), is one of the
most common constituents of diets worldwide and is reported
to possess antioxidant, anti-inflammatory, antiseptic and
carminative properties (80). In Ayurvedic and traditional
Sino–Japanese medicine systems, ginger has been used for
thousands of years to treat inflammatory and rheumatic dis-
eases. The major constituents of ginger include volatile oils,
oleoresin (gingerol), linoleic acid and trace elements such as
magnesium, phosphorus and potassium. The pungent phenolic
constituent of ginger, [6]-gingerol, inhibited LPS-induced
iNOS expression and production of NO and other RNS species
in macrophages and blocked peroxynitrite-induced oxidation
and nitration reactions in vitro (81). These results suggest
that [6]-gingerol is a potent inhibitor of NO synthesis and
also an effective protector against peroxynitrite-mediated
damage. Another in vitro study showed that ginger extract
was effective in inhibiting production of PGE2 and TNF-a
and COX-2 expression in human synoviocytes by regulating
NF-kB activation and degradation of its inhibitor IkBa (82).
Anti-inflammatory activities of silica gel chromatography
fractions of ginger have also been tested using an in vitro
PGE2 assay. Results showed that most of the fractions contain-
ing gingerols and/or gingerol derivatives were excellent
inhibitors of LPS-induced PGE2 production (83). Ginger
extract administered daily for 4 weeks, either orally or
intraperitoneally caused significant reduction in PGE2 levels
in rats (82).
In other studies, ginger alleviates pain and associated
symptoms in patients suffering from OA. In a randomized,
double-blind, placebo-controlled trial of the effects of ginger
extract on knee OA, 63% of the patients in the ginger extract
group experienced reduction in knee pain on standing versus
50% in the placebo group (84). It was concluded that a highly
purified and standardized ginger extract had a statistically sig-
nificant effect on reducing symptoms of OA of the knee. There
was a good safety profile, with mostly mild GI adverse events
in the ginger extract group. The beneficial effects of ginger
were attributed to its ability to inhibit COX and LOX pathways
resulting in the blockade of PGE2 and LTB4 production
in affected joints (77,78). More recently, in a randomized,
double-blind, placebo-controlled, crossover study in patients
with OA, patients in the ginger extract group showed statistic-
ally significant effect in the first period of treatment
before crossover (85). In a limited study with RA patients,
Srivastava and Mustafa (86) reported that ginger was effective
in relieving pain and swelling in the joints of seven RA
patients. Based on this limited information, it is difficult to
determine whether use of ginger or ginger oils will be benefi-
cial in treating of OA or RA. However, these results are
strong enough to advocate and support further studies on the
effects of ginger in OA and RA in both animal models and
clinical studies.
Conclusions
At present, the current modalities for treating arthritis are
symptomatic and have not been shown to either block or
reverse the cartilage degradation and joint destruction. This
has resulted in heightened interest in the use of CAM therapies
for the treatment of arthritis. However, much of the current
research is focused on the identification, isolation and charac-
terization of active principle(s) from crude extracts of known
medicinal plants or herbs, often overlooking the fact
that strong synergism of several constituents in the crude
drug may prove more potent and effective than any single
purified compound and this may help to nullify the toxic
effects of individual constituents (24). This attractive hypo-
thesis encourages further studies but demands rigorous
experimentation. Once the underlying molecular mechan-
ism(s) for the observed anti-inflammatory and chondroprotect-
ive effects of nutraceuticals are elucidated, their health
benefits may be exploited to develop new and better modalities
for treating degenerative and inflammatory joint diseases.
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